Paragon Biosciences is a firm that deals with research and investment in the field of biotechnology. The firm is committed to coming up with treatment methods for people who suffer from medical conditions which have no treatment as of now. Jeffrey Aronin is the founder of Paragon Sciences. He created it because he felt that patients who are in need of medical treatment should be assisted in the quickest way possible to get the right medication. Paragon Biosciences is a combination of companies which have combined efforts to carry out research and develop medicine for the rare conditions which mainly fall into the categories of immune system, nervous system, and rare dermatologic conditions.
Paragon Biosciences works on the basis of first identifying a rare condition which needs a solution and then goes to an extra step of bringing research companies together, which will do the actual research work. The main work of Jeffrey Aronin is to ensure that the researchers are facilitated in carrying out the research. Paragon Biosciences takes a perspective of not only being a medical company but also an investment firm which supports research for treatment. The company has had good progress so far, and the FDA has approved 13 of its medicines. Currently, there are over 6,000 diseases which have no cure, and Paragon Biosciences aim to bring this number down significantly.
Paragon Biosciences under the leadership of Jeffery Aronin is also interested in giving back to the community. They have been supporting many organizations which promote healthcare services, especially at the community level.
Jeffrey Aronin has been in the healthcare sector long enough to experience the challenges that are in the industry. He has been dealing with biotechnologies for the past 20 years. As the CEO of Paragon Biosciences, he is focused on solving the challenges that he has noticed to be in this industry. It is the experience that he has that gives him insight into the development of medicine for rare conditions.
Jeffrey Aronin has positioned himself in a position where he is able to bring the financial and medical aspect of the ongoing research together. In short, he is able to source for financing for the medical research.